TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05703971: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Sponsor: Genprex, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 62 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,356,200

Rescue Site Savings

+$1,570,800

Unlock Full NCT05703971 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05703971 Rescue Dossier →